Close Menu

Drug companies are setting up R&D arms in China, staffing them with local scientists or expat-trained Chinese scientists, to encourage innovative drug research in the country. The GSK R&D center in Shanghai will have a first-year operating budget of $40 million, and AstraZeneca’s Innovation Center China was set up in June 2006 to develop drugs for gastric tract and liver cancers that are prevalent in China.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.